Show simple item record

dc.contributor.authorSamuel, M
dc.contributor.authorKisely, S
dc.contributor.authorRhys-Gill, E
dc.contributor.authorRoberts, A
dc.contributor.authorAddis, S
dc.contributor.authorAlderton, D
dc.contributor.authorPreston, N
dc.contributor.authorCastle, D
dc.date.accessioned2017-05-03T11:46:09Z
dc.date.available2017-05-03T11:46:09Z
dc.date.issued2003
dc.date.modified2010-08-16T06:48:18Z
dc.identifier.issn0963-8237
dc.identifier.doi10.1080/09638230310001603573
dc.identifier.urihttp://hdl.handle.net/10072/33474
dc.description.abstractObjectives: To compare the 12-month clinical outcome of patients attending a depot clinic who were changed to oral atypical antipsychotic medication, with those who remained on depot preparations. Method: A systematic review of the case records of all patients aged between 18 and 65 attending the depot clinic at Fremantle Hospital, Western Australia. Results: The records of 72 patients were identified (mean age 43.3 years; duration of illness 8.5 years; 37% female); 71% had schizophrenia. Twenty-five patients were successfully switched to an oral atypical antipsychotic (34%), 34 controls remained on a depot (47%), five were managed on a combination of a depot and an atypical, and eight returned to depot medication after a trial of an oral atypical. At 12 month follow-up, patients on oral atypicals showed significant improvement on the CGI (z=-2.57, p=0.01), less akathisia (z=-2.12, p=0.03), and reduced use of antiparkinsonian medication (z=-1.97, p=0.04); these changes were not mirrored in the controls. On multivariate analysis, being on an atypical agent was an independent predictor of improved outcome as measured by the CGI scale (t=-2.1, p=0.04), but also weight gain (t=-2.9, p=0.006). Conclusions: This retrospective survey reveals that a proportion of patients on depot antipsychotic medication can successfully be changed to oral atypical agents, with enhanced clinical outcomes. Declaration of interest: This study was supported by an investigator-initiated grant to SK and DC from Janssen Cilag. DC has received honoraria, travel support, and other grant funding from both Janssen Cilag and Eli Lilly.
dc.description.peerreviewedYes
dc.description.publicationstatusYes
dc.languageEnglish
dc.language.isoeng
dc.publisherTaylor & Francis
dc.publisher.placeUK
dc.relation.ispartofpagefrom513
dc.relation.ispartofpageto519
dc.relation.ispartofissue5
dc.relation.ispartofjournalJournal of Mental Health
dc.relation.ispartofvolume12
dc.subject.fieldofresearchClinical sciences
dc.subject.fieldofresearchClinical sciences not elsewhere classified
dc.subject.fieldofresearchcode3202
dc.subject.fieldofresearchcode320299
dc.titleSwitching patients to atypical oral antipsychotics: A retrospective audit of depot clinic attenders
dc.typeJournal article
dc.type.descriptionC1 - Articles
dc.type.codeC - Journal Articles
gro.date.issued2003
gro.hasfulltextNo Full Text
gro.griffith.authorKisely, Steve R.


Files in this item

FilesSizeFormatView

There are no files associated with this item.

This item appears in the following Collection(s)

  • Journal articles
    Contains articles published by Griffith authors in scholarly journals.

Show simple item record